Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is moving its lead candidate Lucid-MS into a randomized, double-blind, placebo-controlled Phase 2 trial for multiple sclerosis (MS) after the U.S. Food and Drug Administration cleared its Investigational New Drug application. The clearance represents a critical milestone for a therapy that takes a fundamentally different approach to MS treatment. Rather than suppressing the immune system, Lucid-MS is a patented, first-in-class, non-covalent inhibitor of peptidyl arginine deiminase 2 (PAD2) designed to target demyelination directly. If successful, this mechanism could offer an alternative for patients who do not respond adequately to existing immunomodulatory therapies or who seek to avoid long-term immune suppression.
The announcement also highlights Quantum's research collaboration with Massachusetts General Hospital and Harvard Medical School involving the [¹⁸F]3F4AP PET imaging tracer, which is being evaluated as a method to visualize and measure demyelination. This collaboration could provide a valuable biomarker tool for assessing treatment response in MS trials, potentially accelerating drug development and enabling more precise patient selection. The ability to directly measure myelin repair would be a significant advance for the field, as current imaging techniques have limitations in quantifying demyelination and remyelination.
The broader context of the news places Quantum BioPharma alongside other companies advancing therapies in areas of unmet medical need. Novartis AG (NYSE: NVS) recently received FDA approval for Pluvicto® in combination with an androgen receptor pathway inhibitor for certain patients with metastatic hormone-sensitive prostate cancer. Merck & Co. Inc. (NYSE: MRK) had its supplemental Biologics License Application for ENFLONSIA™ accepted by the FDA to expand its indication for certain children at increased risk for severe respiratory syncytial virus disease. TG Therapeutics Inc. (NASDAQ: TGTX) initiated a Phase 2 trial of BRIUMVI® in adults with treatment-resistant schizophrenia. Bristol-Myers Squibb Company (NYSE: BMY) reported positive Phase 2 results from the registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel in heavily pretreated relapsed and refractory multiple myeloma. These developments underscore the active pursuit of innovative therapies across a range of serious diseases.
For Quantum BioPharma, the FDA clearance de-risks the next stage of development for Lucid-MS and positions the company to potentially address a major unmet need in MS, where current treatments primarily focus on immune modulation rather than direct myelin protection or repair. The Phase 2 trial will be a key test of whether PAD2 inhibition can translate into clinical benefit. Success could also validate the company's broader pipeline strategy, which includes other assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company's retained ownership in Unbuzzd Wellness Inc. and royalty agreements provide additional financial flexibility.
To view the full press release, visit https://ibn.fm/lCey9. For more information about Quantum BioPharma, visit the company's newsroom at https://ibn.fm/QNTM.
